Cargando…
Non‐parallel anti‐tumour effects of pembrolizumab: a case of cardial tamponade
We present the case of a 70‐year‐old man with stage IV lung adenocarcinoma. He was treated with pembrolizumab, a programmed cell death‐1 (PD‐1) inhibitor, as a first‐line therapy. After six cycles of pembrolizumab, he suddenly developed cardiac tamponade. With the exception of newly massive malignan...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354230/ https://www.ncbi.nlm.nih.gov/pubmed/30733865 http://dx.doi.org/10.1002/rcr2.404 |